|
|
Volumn 10, Issue 11, 2009, Pages 1031-1032
|
|
Pemetrexed approved for the first-line treatment of non-small-cell lung cancer: summary of the NICE appraisal.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
CISPLATIN;
DRUG DERIVATIVE;
GLUTAMIC ACID DERIVATIVE;
GUANINE;
PEMETREXED;
COST BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG COST;
ECONOMICS;
HUMAN;
LUNG NON SMALL CELL CANCER;
LUNG TUMOR;
NOTE;
PRACTICE GUIDELINE;
TREATMENT OUTCOME;
UNITED KINGDOM;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, NON-SMALL-CELL LUNG;
CISPLATIN;
COST-BENEFIT ANALYSIS;
DRUG APPROVAL;
DRUG COSTS;
GLUTAMATES;
GREAT BRITAIN;
GUANINE;
HUMANS;
LUNG NEOPLASMS;
PRACTICE GUIDELINES AS TOPIC;
TREATMENT OUTCOME;
MLCS;
MLOWN;
|
|
EID: 79952701230
PISSN: None
EISSN: 14745488
Source Type: Journal
DOI: 10.1016/s1470-2045(09)70289-x Document Type: Note |
|
Times cited : (5)
|
|
References (0)
|
